EXTH-70. PRECLINICAL TRIALS OF THE ANTIBODY-DRUG CONJUGATE TISOTUMAB VEDOTIN IN ADULT-TYPE DIFFUSE GLIOMAS
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae165.1000
Abstract: The gene F3, encoding Tissue Factor (TF), is expressed in many cancers and contributes to their malignancy. Our previous work showed that, among adult-type diffuse gliomas, IDH wild-type (IDHwt) glioblastomas (GBM) express more TF than… read more here.
Keywords: idhwt gbm; mice; gliomas; adult type ... See more keywords
Targeting BCAT1 combined with α-ketoglutarate triggers metabolic synthetic lethality in glioblastoma.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer research"
DOI: 10.1158/0008-5472.can-21-3868
Abstract: Branched-chain amino acid transaminase 1 (BCAT1) is upregulated selectively in human isocitrate dehydrogenase (IDH) wildtype (WT) but not mutant glioblastoma multiforme (GBM) and promotes IDHWT GBM growth. Through a metabolic synthetic lethal screen, we report… read more here.
Keywords: glioblastoma; synthetic lethality; metabolic synthetic; idhwt gbm ... See more keywords
Cancer immune profiling unveils biomarkers, immunological pathways, and cell type score associated with glioblastoma patients’ survival
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221127678
Abstract: Introduction: Glioblastoma (GBM), isocitrate dehydrogenase (IDH) wild-type (IDHwt), and grade 4 astrocytomas, IDH mutant (IDHmut), are the most common and aggressive primary malignant brain tumors in adults. A better understanding of the tumor immune microenvironment… read more here.
Keywords: oncology; immune profiling; cancer immune; idhwt gbm ... See more keywords